Phenylboronic acid magnetic sphere kit for enrichment of multi-cancer exosomes and preparation method of phenylboronic acid magnetic sphere kit
The magnetic ball kit prepared by using phenylboronic acid-functionalized agarose microspheres solved the problems of poor exosome enrichment and high cost, and achieved efficient and simple separation of exosomes from multiple cancer types, improving the adsorption capacity and purity of exosomes.
Patent Information
- Application Number
- CN202610373813.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-25
- Publication Date
- 2026-04-21
AI Technical Summary
Existing technologies have poor exosome enrichment effects, low sensitivity, and high preparation costs. Traditional methods are complex to operate and difficult to efficiently separate exosomes from multiple cancer types.
Using phenylboronic acid-functionalized agarose microspheres as magnetic spheres, and taking advantage of their reversible binding properties with the cis-diol structure of glycoproteins on the surface of exosomes, exosomes are captured under alkaline conditions and then released under acidic conditions, thus preparing a magnetic sphere kit with high adsorption capacity, excellent specificity, superparamagnetism, and good suspension.
It achieves efficient and simple exosome enrichment, significantly improves the adsorption capacity and purity of exosomes, simplifies the operation process, reduces the preparation cost, and is applicable to the separation of exosomes from various cancers.
Smart Images

Figure CN121896172A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of reagent kit technology, specifically to a phenylboronic acid magnetic bead reagent kit for enriching exosomes from multiple cancer types and its preparation method. Background Technology
[0002] Exosomes are vesicle structures with a diameter of 30-200 nm secreted by cells. Released into body fluids by various cell types, exosomes carry biomolecules such as nucleic acids, proteins, and metabolites derived from their parent cells. The phospholipid bilayer structure of exosomes protects their contents and ensures their stability in body fluids. With the deepening research into exosomes in the biomedical field, they have been widely applied in cancer treatment, pulmonary fibrosis therapy, medical aesthetics, and food. Therefore, developing a method for extracting high-purity, high-yield exosomes has become a prerequisite for their application in biomedicine. Currently, there are many methods and types of exosome extraction, but the content, purity, and activity of the extracted exosomes vary to some extent, each with its own advantages and disadvantages. Currently, the main methods for isolating exosomes include: centrifugation (differential centrifugation, density gradient centrifugation, rate zoning centrifugation, ultracentrifugation, etc.), ultrafiltration (ultrafiltration technology, gel filtration chromatography), precipitation (polyethylene glycol, acetate solution), immunoassay (magnetic bead method, ELISA method, flow cytometry, microfluidics), and exosome extraction kits.
[0003] Isolating exosomes from the complex body fluid environment is crucial for exosome research. Ultracentrifugation is considered the "gold standard" for exosome isolation, but it suffers from drawbacks such as long processing time, reliance on ultracentrifuges, and low exosome yield and purity, hindering clinical application and widespread adoption. Exosomes enriched by polyethylene glycol precipitation are easily contaminated by proteins and lipids, resulting in low purity. Other traditional exosome isolation methods, such as ultrafiltration and size exclusion methods, require multiple sample loading and changing when separating large-volume samples, leading to cumbersome operations and long processing times. To improve the selectivity of exosome isolation, affinity capture strategies based on molecular recognition are becoming increasingly attractive. The high binding affinity between specific exosome markers and corresponding ligands, such as antibodies, peptides, and aptamers, can enhance the selectivity and specificity of exosome enrichment.
[0004] Although commercial kits for immunomagnetic bead assays and other methods have been widely developed, existing magnetic materials for biomolecule separation, especially nanoscale magnetic beads, have limitations when used for the concentration of purified exosomes: such as limited specific surface area and low adsorption capacity; they are more prone to aggregation, affecting dispersibility; and after separation in a magnetic field, their nanoscale size may make it difficult to completely separate them from exosomes of similar size in subsequent elution steps, causing cross-contamination.
[0005] Based on this, the retrieved patent documents are as follows:
[0006] This document, published in China (CN114940699A) on August 26, 2022, discloses a large-scale exosome enrichment technology to reduce exosome damage. The technology mainly includes the following operating units: a raw material supply unit, a first storage tank, a second storage tank, a first filter, a second filter, a third filter, a buffer supply unit, and a pressure regulating device. The first filter consists of several filter membranes that allow exosomes to pass through while retaining large impurities such as cell debris and large molecular vesicles, connected in a cross-flow manner to increase product throughput. The second filter contains several hollow fiber ultrafiltration membranes to block and enrich exosomes. The third filter prevents bacteria from contaminating the exosome preparation solution, improving product quality. This invention is simple in design and reasonable in structure, solving the problems of small exosome collection volume, complex operation, and poor product quality in existing technologies.
[0007] This document, published in China (CN115678832A) on February 3, 2023, discloses an exosome composition comprising an enriched exosome population. The exosome composition is obtained directly by separation and ultrafiltration, rather than by formulation, and a method for producing the exosome composition is provided. However, the enrichment effect is still unsatisfactory.
[0008] Therefore, there is a need to develop a phenylboronic acid magnetic bead kit with good enrichment effect and simple operation for the enrichment of exosomes from multiple cancer types, as well as its preparation method. Summary of the Invention
[0009] To address the shortcomings of existing technologies, such as poor enrichment effects and high preparation costs, this invention provides a kit for enriching exosomes. This kit uses phenylboronic acid-functionalized agarose microspheres as magnetic spheres. Utilizing the reversible binding property of phenylboronic acid to the cis-diol structure of glycoproteins on the exosome surface, exosomes are captured under alkaline conditions and then released under acidic conditions. These magnetic spheres possess high adsorption capacity, excellent specificity, superparamagnetism, good suspension properties, and recyclability, and are simple and quick to operate.
[0010] In order to achieve the above objectives, the present invention aims to provide: This invention provides a phenylboronic acid magnetic bead kit for enriching exosomes from multiple cancer types, and related technologies, to solve the technical problems of poor enrichment effect, low sensitivity and high preparation cost in the prior art, or a combination thereof.
[0011] Terminology Explanation: Unless otherwise defined, all technical terms in this document have the same meanings as commonly understood by one of ordinary skill in the art to which the subject matter of the claims pertains. Unless otherwise stated, all patents, patent inventions, and publications cited in this document are incorporated herein by reference in their entirety. If multiple definitions exist for terms in this document, the definitions in this chapter shall prevail.
[0012] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.
[0013] Unless otherwise stated, conventional methods within the scope of the art, such as mixing and stirring, shall be used.
[0014] The term "exosome" refers to any extracellular vesicle derived from any bodily fluid (e.g., blood) of a human or animal, including but not limited to autologous exosomes, universal donor exosomes, allogeneic exosomes, and modified exosomes.
[0015] Exosomes, either directly or as a delivery medium for drug payloads, are being actively explored as therapeutic agents. Compared to liposomes, injected exosomes are more efficient at entering other cells, can deliver functional payloads with minimal immune clearance, and exhibit good tolerability upon exogenous administration.
[0016] Exosome compositions can be derived from any number of tissue sources, such as muscle, fat, organs, or bone or bone marrow. Various cells can be used to prepare the exosome compositions disclosed herein. Specifically, exosome compositions can be derived from cells, such as eukaryotic organisms or cell lines, or from plants or animals. Cells can be genetically modified, such as stem cells. In some embodiments, stem cells are embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), hematopoietic stem cell transplantation (HSCT), or induced pluripotent stem cells (iPS cells or iPSCs).
[0017] Unless specifically defined herein, the use of various commercially available products herein employs standard techniques. For example, they may be implemented in a manner known in the art or as described in this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.
[0018] The terms “optional / arbitrary” or “optionally / arbitrarily” mean that the event or situation described below may or may not occur, including both the occurrence and non-occurrence of the event or situation.
[0019] In a first aspect, the present invention provides a phenylboronic acid magnetic bead kit for the enrichment of exosomes from multiple cancer types. The kit comprises A-PBA magnetic beads, binding buffer, elution buffer, and neutralization buffer.
[0020] The binding buffer is PBS with pH=2; the elution buffer is PBS with pH=7 containing 500 mM NaCl; and the neutralization solution is 0.1M NaOH.
[0021] A further technical solution is that the preparation process of the A-PBA magnetic sphere is as follows: (1) Preparation of amino-modified iron oxide magnetic spheres (NH2-Fe3O4): FeCl3·6H2O and anhydrous sodium acetate were dissolved in ethylene glycol, mixed and then 1,6-hexanediamine was added. After hydrothermal reaction and washing, NH2-Fe3O4 was obtained. (2) Preparation of agarose magnetic spheres (Fe3O4@Aga): Agarose aqueous solution containing NH2-Fe3O4 was mixed with an oil solution, and after high-speed shear emulsification and alternating hot and cold solidification, Fe3O4@Aga microspheres were obtained by washing. (3) Epoxy crosslinking: Fe3O4@Aga microspheres were reacted with a bis-epoxy crosslinking agent (BDGE) under alkaline conditions to obtain epoxy crosslinked magnetic agarose microspheres (A-BDGE). (4) Connecting polyethyleneimine (PEI): A-BDGE microspheres are reacted with polyethyleneimine (PEI) solution and connected to the amino group of PEI through ring opening of epoxy groups to obtain PEI-grafted magnetic agarose microspheres (A-PEI). (5) Connecting phenylboronic acid: A-PEI microspheres are reacted with phenylboronic acid derivatives containing aldehyde groups in the presence of a reducing agent. Through the reduction amination reaction of aldehyde groups with amino groups on PEI, phenylboronic acid groups are immobilized on the surface of microspheres to obtain the final product A-PBA magnetic spheres.
[0022] in, The mass ratio of FeCl3·6H2O and anhydrous sodium acetate in step (1) above is 1:1-4; Preferably, the mass ratio of FeCl3·6H2O to anhydrous sodium acetate is 1:2-3; More preferably, the mass ratio of FeCl3·6H2O to anhydrous sodium acetate is 1:2.
[0023] The volume-to-mass ratio of ethylene glycol and FeCl3·6H2O in step (1) above is 12-20 mL: 1 g; Preferably, the volume-to-mass ratio of ethylene glycol to FeCl3·6H2O is 15-18 mL:1 g; More preferably, the volume-to-mass ratio of ethylene glycol to FeCl3·6H2O is 15 mL: 1 g.
[0024] The mass ratio of 1,6-hexanediamine and FeCl3·6H2O in step (1) above is 5-8:1; Preferably, the mass ratio of 1,6-hexanediamine to FeCl3·6H2O is 6-7:1; More preferably, the mass ratio of 1,6-hexanediamine to FeCl3·6H2O is 6.5:1.
[0025] The reaction temperature described in step (1) above is 190-210℃; the reaction time is 4-8 h. Preferably, the reaction temperature is 198°C and the reaction time is 6 hours.
[0026] The oil phase solution mentioned in step (2) above is a solution composed of liquid paraffin and Span 80, and the volume ratio of liquid paraffin to Span 80 is 25-30:1; preferably 26:1.
[0027] The aqueous solution mentioned in step (2) above is a mixed suspension of agarose solution and NH2-Fe3O4. The mass concentration of the agarose solution is 3-5%, preferably 4%; the volume of the agarose solution is 0.8-1.2% of the mass of NH2-Fe3O4; preferably 1.0%.
[0028] The specific steps of step (2) above are as follows: The oil phase solution was preheated at 75-85℃; the aqueous phase solution was stirred and mixed at 90-95℃ and 800-1200 rpm, and then quickly added to the preheated oil phase. The mixture was emulsified at 18000-22000 rpm in a water bath at 75-85℃ for 10-20 min, and then transferred to an ice bath for another 8-15 min to obtain the product. The product was washed successively with petroleum ether, anhydrous ethanol and deionized water to obtain Fe3O4@Aga.
[0029] Preferably, the specific steps of step (2) above are as follows: The oil phase solution was preheated at 80°C; the aqueous phase solution was stirred and mixed at 95°C and 1000 rpm, and then quickly added to the preheated oil phase. The mixture was emulsified at 20000 rpm in an 80°C water bath for 15 min, and then transferred to an ice bath for another 15 min to obtain the product. The product was washed successively with petroleum ether, anhydrous ethanol and deionized water to obtain Fe3O4@Aga.
[0030] The alkaline solution mentioned in step (3) above is a sodium hydroxide solution containing NaBH4; the concentration of the sodium hydroxide solution is 0.5-1.0 mol / L, preferably 0.6 mol / L; the concentration of NaBH4 in the sodium hydroxide solution is 1-3 mg / mL, preferably 2 mg / mL; The mass-to-volume ratio of the Fe3O4@Aga microspheres to the sodium hydroxide solution is 1 mg: 0.1-0.4 mL; Preferably, the mass-to-volume ratio of the Fe3O4@Aga microspheres to the sodium hydroxide solution is 1 mg: 0.2 mL.
[0031] The specific steps of step (3) above are as follows: Fe3O4@Aga microspheres were mixed with NaOH solution and stirred at 30-40℃ and 120-180 rpm for 20-40 min. Then BDGE and DMSO were added, wherein the volume-to-mass ratio of BDGE to Fe3O4@Aga microspheres was 150-200 μL:1 mg; the volume ratio of DMSO to BDGE was 0.5-0.8:1, and the reaction was continued for 4-8 h. After the reaction was completed, the mixture was washed with deionized water to obtain A-BDGE.
[0032] Preferably, the specific steps of step (3) above are as follows: 50 mg of Fe3O4@Aga microspheres were mixed with 10 ml of NaOH solution and stirred at 35 °C and 150 rpm for 30 min. Then, 8 mL of BDGE and 5 mL of DMSO were added, and the reaction was continued for 6 h. After the reaction was completed, the mixture was washed with deionized water to obtain A-BDGE.
[0033] The mass ratio of A-BDGE microspheres to polyethyleneimine (PEI) in step (4) above is 1:40-60; preferably 1:50.
[0034] The polyethyleneimine (PEI) solution mentioned in step (4) above is a sodium bicarbonate aqueous solution of polyethyleneimine (PEI). The preparation method is as follows: weigh PEI and dissolve it in a 50-100 mmol / L sodium bicarbonate aqueous solution. The volume-to-mass ratio of the sodium bicarbonate aqueous solution to PEI is 2-4 mL: 1 g.
[0035] Preferably, the concentration of the sodium bicarbonate aqueous solution is 50 mmol / L; the volume-to-mass ratio of the sodium bicarbonate aqueous solution to PEI is 4 mL: 1 g.
[0036] The reaction conditions for step (4) above are 65-75℃ and 300-500 rpm for 10-14h; preferably 70℃ and 400 rpm for 12h.
[0037] The phenylboronic acid derivative containing an aldehyde group mentioned in step (5) above is 2,4-difluoro-3-formylphenylboronic acid.
[0038] The reducing agent mentioned in step (5) above is sodium cyanoborohydride.
[0039] The specific steps of step (5) above are as follows: A-PEI microspheres are added to an anhydrous ethanol solution containing sodium cyanoborohydride, ultrasonically dispersed, and then 2,4-difluoro-3-formylphenylboronic acid is added. The mixture is shaken at room temperature for 10-14 h. After the reaction is completed, the mixture is washed alternately with ethanol and pure water to obtain A-PBA.
[0040] The concentration of sodium cyanoborohydride in the anhydrous ethanol containing sodium cyanoborohydride is 0.5-2.0%, preferably 1.0%.
[0041] The volume-to-mass ratio of the anhydrous ethanol solution to the A-PEI microspheres is 1 mL: 1-4 mg; preferably 1 mL: 2.5 mg.
[0042] The mass ratio of 2,4-difluoro-3-carboxyphenylboronic acid to A-PEI microspheres is 0.8-1.2:1; preferably 1:1.
[0043] As a preferred embodiment, the method for preparing the A-PBA magnetic spheres includes the following steps: (1) Preparation of amino-modified iron oxide magnetic spheres: FeCl3•6H2O and anhydrous sodium acetate powder were weighed in a 1:2 mass ratio, and ethylene glycol was added to each. The mixture was then sonicated to dissolve the powder, yielding anhydrous sodium acetate ethylene glycol solution and FeCl3•6H2O ethylene glycol solution. The anhydrous sodium acetate ethylene glycol solution was poured into the FeCl3•6H2O ethylene glycol solution and stirred until homogeneous to obtain a mixed solution. Then, 1,6-hexanediamine (6.5 times the mass of FeCl3•6H2O) was added to the mixed solution, and the mixture was sonicated until homogeneous. The mixture was then poured into a high-temperature and high-pressure reactor and reacted at 198℃ for 6 h. After the reaction was completed, the product was washed several times with anhydrous ethanol and pure water to obtain amino-modified iron oxide magnetic spheres, abbreviated as NH2-Fe3O4.
[0044] (2) Preparation of agarose magnetic beads: The oil phase consisted of a mixture of liquid paraffin and Span 80 at a volume ratio of 26:1, preheated in an 80°C water bath. The aqueous phase consisted of a mixed suspension of 4% agarose solution and NH2-Fe3O4 magnetic balls at a volume ratio of 1:10, mechanically stirred at 1000 rpm in a 95°C water bath until homogeneous. The mixed sugar suspension was quickly transferred to the oil phase. The mixture was emulsified in an 80°C water bath at 20,000 rpm for 15 min using a high-speed shear mill, followed by emulsification in an ice bath for another 10 min. The product was washed several times with petroleum ether, anhydrous ethanol, and deionized water to obtain Fe3O4@Aga. (3) Cross-linked epoxy groups: Fe3O4@Aga microspheres (5:1 by mass / volume ratio) were mixed with a 0.6 mol / L NaOH solution containing 2 mg / mL NaBH4. The mixture was stirred at 150 rpm for 30 min in a 35°C water bath. Then, BDGE and DMSO (1.6:1 by volume ratio) were added, and the reaction was continued for 6 h to obtain Fe3O4@Aga-BDGE microspheres. The Fe3O4@Aga-BDGE microspheres were washed several times with deionized water to obtain A-BDGE. (4) Connecting polyethyleneimine: A homogeneous solution was obtained by mixing PEI 1800he and 50 mmol / L sodium bicarbonate aqueous solution at a mass-to-volume ratio of 1:3.2. This solution was then added to a beaker containing 50 mg of A-BDGE microspheres, and the mixture was ultrasonically dispersed and reacted at 70℃ and 400 rpm for 12 h. After the reaction was completed, the microspheres were washed with ultrapure water and magnetically separated to obtain PEI-grafted magnetic agarose microspheres, which are A-PEI. (5) Connecting phenylboronic acid: Weigh A-PEI microspheres (2.5:1 by mass ratio) and anhydrous ethanol containing 1% sodium cyanoborohydride, and ultrasonically disperse them into a homogeneous solution. Then, add 50 mg of 2,4-difluoro-3-carboxyphenylboronic acid (2,4-DFPBA) to the homogeneous solution and shake in a shaker at room temperature for 12 h. After the reaction, wash the solution with ethanol and pure water alternately several times to obtain phenylboronic acid-functionalized magnetic agarose microspheres.
[0045] The present invention also provides the application of the kit in enriching and isolating exosomes from plasma, serum, urine, breast milk, cerebrospinal fluid, tumor ascites, saliva, and cell culture supernatant.
[0046] The present invention also provides a method for enriching and isolating exosomes using the above-mentioned kit, comprising the following steps: S1. Collect the culture medium. Select A549 cells in good growth condition and culture them until the culture dish is 70% full; discard the culture medium, wash twice with PBS, culture A549 cells in RIPM 1640 complete culture medium prepared with exosome-free serum for 3 days, and collect the culture medium and store it temporarily at 4°C. S2, Culture medium pretreatment Before ultracentrifugation, the culture medium was pretreated to remove cell debris and large extracellular vesicles. The culture medium was centrifuged at 1000 g for 15 min at 4 °C to remove dead cells; centrifuged at 2500 g for 20 min at 4 °C to remove cell debris; and centrifuged at 10000 g for 30 min at 4 °C to remove large extracellular vesicles. The pretreated culture medium was then temporarily stored at 4 °C.
[0047] S3, Ultracentrifugation The pretreated culture medium was centrifuged using an ultracentrifuge at 100,000g for 70 min, and the supernatant was discarded after centrifugation. S4, Exosome enrichment Exosomes precipitated at the bottom of the ultracentrifuge tube were resuspended in 1 ml binding buffer and the protein concentration was determined. A-PBA magnetic beads were added at a ratio of 0.3-0.5 mg A-PBA magnetic beads to 25 μg / ml protein, and the mixture was shaken at room temperature for 2 hours at a shaking speed of 30 rpm. S5. Elution of exosomes: Discard the supernatant, wash with elution buffer, add 100-200 μL of binding buffer, and elute by shaking at room temperature for 0.5-2 hours. After elution, perform solid-liquid separation using magnetic adsorption. Adjust the pH of the supernatant to 7.0 with 0.1 M NaOH to complete the enrichment.
[0048] This kit can be used for the enrichment of exosomes from a variety of cancers, including lung cancer, breast cancer, colon cancer, or pancreatic cancer.
[0049] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. High enrichment efficiency and capacity: The micron-sized structure provides a larger specific surface area and more binding sites, resulting in extremely high adsorption capacity for exosomes. Western blotting (WB) characterization results showed that the signals of characteristic exosome proteins (such as CD63, TSG101, and CD9) were significantly enhanced after enrichment, demonstrating its excellent enrichment ability.
[0050] 2. Excellent selectivity: The smooth surface of the microsphere structure effectively reduces non-specific protein adsorption. The specific binding of PBA to cis-diol enables it to capture exosomes with high purity from complex biological samples.
[0051] 3. Simple and fast operation: Thanks to its superparamagnetism and micron-sized structure, the magnetic spheres separate rapidly in the magnetic field (within tens of seconds) and do not remain suspended for a long time due to Brownian motion, simplifying the washing and elution steps. The entire enrichment process can be completed in 1-2 hours.
[0052] 4. Good biocompatibility and stability: The agarose matrix has good biocompatibility and causes little damage to the exosome structure. The prepared A-PBA magnetic balls are stable in performance during storage and multiple uses.
[0053] 5. Recyclable and low-cost: The binding of PBA with cis-diol is reversible, and the magnetic beads can be easily eluted and regenerated for repeated use, significantly reducing the cost per use and overcoming the high cost of immunomagnetic beads.
[0054] 6. High versatility: This kit does not depend on specific exosome surface markers and can broadly enrich exosomes expressing cis-diol structures from various sources, making it widely applicable. Attached Figure Description
[0055] Figure 1 Schematic diagram of the preparation route for A-PBA microspheres.
[0056] Figure 2 Image of A-PBA microspheres using scanning electron microscopy (SEM).
[0057] Figure 3 Hysteresis curves of vibrating sample magnetometer (VSM) of A-PBA microspheres.
[0058] Figure 4 Fourier transform infrared (FT-IR) spectra of the products at each stage of the A-PBA preparation process.
[0059] Figure 5 Performance diagram of A-PBA microspheres cyclic adsorption-desorption OVA.
[0060] Figure 6 Adsorption performance of A-PBA microspheres after different storage times.
[0061] Figure 7 Schematic diagram of the process for enriching exosomes using A-PBA microspheres.
[0062] Figure 8 : Results of Western Blot detection of exosome marker proteins (Alix, CD63, CD9) before and after enrichment; where 1 is the exosome solution before separation with A-PBA magnetic beads, 2 is the exosomes enriched with A-PBA magnetic beads, and 3 is the solution after exosomes are adsorbed with A-PBA magnetic beads.
[0063] Figure 9A comparison of the adsorption effects of magnetic spheres with different functional groups at different salt concentrations.
[0064] Figure 10 A comparison of the adsorption capacity of magnetic spheres with different functional groups to exosomes at different salt concentrations.
[0065] Figure 11 Comparison of the adsorption effects of magnetic balls with different dosages.
[0066] Figure 12 : Comparison of adsorption effects of adsorption solutions at different pH values.
[0067] Figure 13 : Comparison of adsorption effects of adsorption solutions at different temperatures.
[0068] Figure 14 : Comparison of adsorption effects of adsorption solutions at different shaking speeds.
[0069] Figure 15 Comparison of elution effects of elution solutions with different pH values.
[0070] Figure 16 Comparison of elution effects of elution solutions at different times.
[0071] Figure 17 Comparison of elution effects with different volumes of eluent. Detailed Implementation
[0072] The present invention will be further described in detail below through specific embodiments, but the scope of protection of the present invention is not limited thereto.
[0073] Example: Preparation method of A-PBA magnetic spheres The preparation steps of A-PBA magnetic balls are as follows: Figure 1 As shown, specifically: (1) Preparation of amino-modified iron oxide magnetic spheres: 2.0 g of FeCl3•6H2O and 4.0 g of anhydrous sodium acetate powder were weighed separately, and 30 ml of ethylene glycol was added to each. The solutions were dissolved by sonication to obtain FeCl3•6H2O ethylene glycol solution and anhydrous sodium acetate ethylene glycol solution, respectively. The anhydrous sodium acetate ethylene glycol solution was poured into the FeCl3•6H2O ethylene glycol solution and stirred evenly to obtain a mixed solution. Then, 13 g of 1,6-hexanediamine was added to the mixed solution and stirred evenly by sonication. The mixture was then poured into a high-temperature and high-pressure reactor and reacted at 198℃ for 6 h. After the reaction was completed, the product was washed several times with anhydrous ethanol and pure water to obtain amino-modified iron oxide magnetic spheres, hereinafter referred to as NH2-Fe3O4. (2) Preparation of agarose magnetic beads: The oil phase consisted of 75 ml of liquid paraffin and 2.8 ml of Span 80, preheated in an 80°C water bath. The aqueous phase consisted of a mixed suspension of 10 ml of 4% agarose solution and 100 mg of NH2-Fe3O4 nanoparticles, mechanically stirred at 1000 rpm in a 95°C water bath until homogeneous. The mixed sugar suspension was quickly transferred to the oil phase. The mixture was emulsified in an 80°C water bath at 20,000 rpm for 15 min using a high-speed shear press, then transferred to an ice bath and emulsified for another 10 min. The product was washed several times with petroleum ether, anhydrous ethanol, and deionized water to obtain Fe3O4@Aga. (3) Cross-linked epoxy groups 50 mg of Fe3O4@Aga microspheres were mixed with 10 mL of 0.6 mol / L NaOH solution containing 2 mg / mL NaBH4. The mixture was stirred at 150 rpm for 30 min in a 35°C water bath. Then, 8 mL of BDGE and 5 mL of DMSO were added, and the reaction was continued for 6 h to obtain Fe3O4@Aga-BDGE microspheres. The Fe3O4@Aga-BDGE microspheres (hereinafter referred to as A-BDGE) were washed several times with deionized water to obtain A-BDGE. (4) Connecting polyethyleneimine: Weigh 50 mg of A-BDGE microspheres and mix 2.5 g of PEI 1800 with 8 ml of 50 mmol / L sodium bicarbonate aqueous solution to form a homogeneous solution. Then, add this solution to a beaker containing 50 mg of A-BDGE microspheres and sonicate to disperse evenly. Transfer the mixture to a 50 ml three-necked flask and react at 70 °C and 400 rpm for 12 h. After the reaction, wash the microspheres six times with ultrapure water, separate them magnetically, and determine their solid content to obtain PEI-grafted magnetic agarose microspheres, which are then obtained as A-PEI. (5) Connecting phenylboronic acid: Weigh 50 mg of A-PEI microspheres and add 20 ml of anhydrous ethanol containing 1% sodium cyanoborohydride. Disperse the microspheres evenly by ultrasonication to obtain a solution. Then add 50 mg of 2,4-difluoro-3-carboxyphenylboronic acid (2,4-DFPBA) to the above solution and shake the mixture in a shaker at room temperature for 12 h. After the reaction is complete, wash the microspheres with ethanol and pure water alternately several times to obtain phenylboronic acid-functionalized magnetic agarose microspheres, which are A-PBA.
[0074] Example 1: Characterization of A-PBA microspheres Through an optical microscope ( Figure 2 Observation showed that A-PBA particles were spherical with a uniform size of approximately 10 μm. VSM testing ( Figure 3 The FT-IR spectrum shows a saturation magnetization of 5.77 emu / g. Figure 4The result shows that A-PBA is at 1296 cm. -1 The presence of a BO characteristic peak at this location confirms the successful introduction of phenylboronic acid.
[0075] Example 2: Adsorption performance of A-PBA for glycoproteins (OVA) Isothermal adsorption experiments showed that the adsorption of OVA by A-PBA conformed more closely to the Langmuir model, with a maximum adsorption capacity Qmax of 252.17 mg / g. Adsorption kinetic experiments indicated that the adsorption process conformed more closely to a pseudo-second-order kinetic model. Specificity experiments showed that the adsorption capacity of OVA by A-PBA was significantly higher than that of other molecules such as cephalexin.
[0076] Example 3: Magnetic Separation and Stability of A-PBA Sedimentation experiments showed that A-PBA could completely settle within 4 minutes under the influence of a magnetic field, achieving rapid separation. Cyclic experiments ( Figure 5 The results show that after five adsorption-desorption cycles, the adsorption capacity remains above 80% of the initial value. Stability test ( Figure 6 The results showed that its adsorption performance did not decrease significantly after 60 days of storage at room temperature.
[0077] Example 4: Western blot was used to detect exosomes before and after enrichment.
[0078] like Figure 8 As shown, 1 is the exosome solution before separation with A-PBA magnetic beads, 2 is the exosomes enriched with A-PBA magnetic beads, and 3 is the supernatant after exosomes are adsorbed with A-PBA magnetic beads; Alix, CD63, and CD9 are exosome marker proteins.
[0079] Experimental results showed that the concentration of exosomes in the initial solution was low, and the expression of marker proteins could not be detected by Western blotting. However, after enrichment with magnetic beads, the concentration of exosomes increased, and the expression of marker proteins could be detected, with bands of Alix, CD63, and CD9 visible. No exosomes were present in the supernatant after adsorption with magnetic beads. These results prove that exosomes have been successfully enriched by A-PBA magnetic beads.
[0080] Basic Application Example: A phenylboronic acid magnetic bead kit for enriching exosomes from multiple cancer types and a method for enriching tumor exosomes. The kit includes: magnetic beads prepared as A-PBA in Example 1; binding buffer as PBS solution; elution buffer as PBS solution containing NaCl; and neutralization solution as NaOH solution.
[0081] The exosome enrichment and elution procedure is attached. Figure 7 Specifically: S1. Collect the culture medium. Select A549 cells in good growth condition and culture them until the culture dish is 70% full; discard the culture medium, wash twice with PBS, culture A549 cells in RIPM 1640 complete culture medium prepared with exosome-free serum for 3 days, and collect the culture medium and store it temporarily at 4°C. S2, Culture medium pretreatment Before ultracentrifugation, the culture medium was pretreated to remove cell debris and large extracellular vesicles. The culture medium was centrifuged at 1000 g for 15 min at 4 °C to remove dead cells; centrifuged at 2500 g for 20 min at 4 °C to remove cell debris; and centrifuged at 10000 g for 30 min at 4 °C to remove large extracellular vesicles. The pretreated culture medium was then temporarily stored at 4 °C.
[0082] S3, Ultracentrifugation The pretreated culture medium was centrifuged using an ultracentrifuge at 100,000g for 70 min, and the supernatant was discarded after centrifugation. S4, Exosome enrichment Exosomes precipitated at the bottom of the ultracentrifuge tube were resuspended in 1 ml binding buffer, protein concentration was measured, A-PBA magnetic beads were added, and the mixture was shaken on a shaker for adsorption. S5. Elution of exosomes: Discard the supernatant, wash with elution buffer, add binding buffer, and elute by shaking at room temperature. After elution, perform solid-liquid separation using magnetic adsorption. Adjust the pH of the supernatant to 7.0 with NaOH to complete the enrichment.
[0083] The following steps are used to optimize the conditions for the above exosome enrichment process: 1. Optimization of conditions for A-PBA elution and enrichment of exosomes: (1) Study on the concentration of added NaCl: In the process of preparing magnetic spheres, four groups were modified in sequence: agarose, namely Fe3O4@Aga prepared in step (2); epoxy group, namely A-BDGE prepared in step (3); PEI, namely A-PEI prepared in step (4); and PBA, namely A-PBA prepared in step (5). It was found that the microspheres modified by these four groups would absorb more or less exosomes, which is the so-called non-specific adsorption. By optimizing the salt concentration to reduce the nonspecific adsorption of magnetic spheres, it was found that the strongest nonspecific adsorption of exosomes was achieved by the PEI group, specifically microsphere A-PEI. Therefore, the adsorption of exosomes by two types of magnetic spheres, A-PEI and A-PBA, was selected as an indicator of nonspecific adsorption. The experimental results are as follows: Figure 9As shown, with increasing salt concentration, the salt concentration at which the difference in adsorption capacity between A-PEI and A-PBA magnetic spheres is largest is 500 mmol / L. Therefore, 500 mmol / L is the preferred NaCl concentration.
[0084] To further verify whether salt concentration can truly reduce the non-specific adsorption of exosomes, four types of magnetic spheres formed during the preparation process—Fe3O4@Aga, A-BDGE, A-PEI, and A-PBA—were used to adsorb exosome solutions with different salt concentrations. The adsorption results are as follows: Figure 10 As shown, for the first three types of magnetic spheres, the adsorption capacity of exosomes in a 500 mmol / L salt solution was lower than that in a 100 mmol / L salt solution, indicating that the decrease in salt concentration does indeed reduce the non-specific adsorption of exosomes. However, the adsorption capacity of exosomes by A-PBA did not decrease significantly, indicating that A-PBA has a stronger specific adsorption capacity for exosomes and is more stable in salt solutions of different concentrations.
[0085] (2) Study on the amount of magnetic balls added: During the study, magnetic beads were added to 1 ml of 25 μg / ml exosome solution at concentrations of 0.1 mg, 0.3 mg, 0.5 mg, 0.7 mg, and 0.9 mg, respectively. The change in exosome concentration was used as a quantitative value to examine the amount of magnetic beads used. See details below. Figure 11 .
[0086] According to the test results, the change in exosome concentration was too small when the magnetic ball dosage was 0.1 mg. When the magnetic ball dosage was greater than 0.3 mg, the change in exosome concentration remained almost unchanged. In order to save costs, the magnetic ball dosage was selected to be 0.3 mg-0.5 mg added to 1 ml of 25 μg / ml exosome solution.
[0087] (3) Study on pH of adsorption solution: Exosomes are active biomolecules, and excessively acidic or alkaline conditions may be detrimental to their activity. Furthermore, pH affects the adsorption performance of phenylboronic acid-modified magnetic beads. Therefore, the pH of the adsorption solution was investigated. Equal amounts of magnetic beads were added to exosome solutions at different pH values, and the adsorption amounts were compared (see the graph). Figure 12 The optimal pH for the adsorption system is 5-7. When pH=1-3, pH<pKa, the specific adsorption of phenylboronic acid is ineffective; when pH=9-11, although the specific adsorption of phenylboronic acid is relatively stable, the exosomes are unstable under alkaline conditions and may be degraded, thus resulting in a low adsorption capacity of A-PBA magnetic beads.
[0088] (4) Study on adsorption temperature: During the adsorption of exosomes, excessively high or low temperatures can affect the quality of the exosomes; therefore, the temperature during the adsorption process was optimized (see...). Figure 13 The optimal temperature for exosomes is 20°C. At lower temperatures, the adsorption capacity of magnetic beads is affected, including the particle movement speed in temperature-responsive solutions, so the adsorption amount of magnetic beads will decrease. At higher temperatures (≥40°C), the degradation rate of exosomes is accelerated, resulting in a decrease in the adsorption amount of magnetic beads.
[0089] (5) Study on the speed of the shaking table: The shaking speed affects the adsorption of exosomes during the adsorption process; therefore, the shaking speed was investigated, and the experimental results are as follows: Figure 14 As shown, it was found that the amount of magnetic ball adsorption first increased, then decreased, and then stabilized with the increase of the shaking speed. The most suitable shaking speed is 30 rpm.
[0090] The optimal conditions for exosome enrichment were determined to be: salt concentration of 500 mmol / L, magnetic beads of 0.3 mg per ml of 25 μg / ml exosome solution, pH of the adsorption solution of 7, adsorption temperature of 20℃, and shaking speed of 30 rpm.
[0091] 2. Optimization of A-PBA elution conditions for exosomes: (1) Study on the pH of the elution solution: Since the adsorption and elution of phenylboronic acid onto exosomes depends on the pH of the elution solution, the pH of the elution solution was optimized, and the results are as follows: Figure 15 As shown, when the pH of the elution solution is ≤2, the exosomes adsorbed on the magnetic beads can be eluted, and the elution volume of the elution solution with pH=1 is higher than that of the elution solution with pH=2. That is, the lower the pH of the solution, the stronger the elution ability of the elution solution. Therefore, the pH of the elution solution is ≤2.
[0092] (2) Study on washout time: Studies have shown that the optimal conditions for exosome eluent are pH ≤ 2, and that eluent with pH = 1 has a greater elution capacity than eluent with pH = 2. However, eluent with pH = 1 causes more damage to exosomes than eluent with pH = 2. To better eluent exosomes and reduce damage from the eluent, the elution time was studied, and the results are as follows: Figure 16 As the elution time increases, the production of exosomes also increases, and the optimal elution time is 2 hours.
[0093] (3) Study on the volume of elution buffer: The volume of the eluent during the elution process was studied using an eluent with pH=1, and the results are as follows: Figure 17As shown, the concentration of exosomes in the eluent gradually decreases with increasing eluent volume, but the total amount of exosomes eluted gradually increases. This may be because a larger eluent volume results in less exosome residue on the magnetic beads, leading to a greater number of exosomes in the solution. Considering the need for exosome enrichment, 100 μL was selected as a suitable eluent volume.
[0094] The optimal conditions for eluting exosomes with A-PBA were determined to be: pH 2 of the elution solution, elution time of 2 h, and elution volume of 100 μL.
[0095] Application Example 1: A phenylboronic acid magnetic bead kit for enriching exosomes from multiple cancer types and a method for enriching tumor exosomes therein. The kit includes: magnetic beads prepared as A-PBA in Example 1; binding buffer as PBS solution with pH=2; elution buffer as PBS solution with pH=7 containing 500 mM NaCl; and neutralization solution as 0.1M NaOH solution.
[0096] The exosome enrichment and elution procedure is attached. Figure 7 Specifically: S1. Collect the culture medium. Select A549 cells in good growth condition and culture them until the culture dish is 70% full; discard the culture medium, wash twice with PBS, culture A549 cells in RIPM 1640 complete culture medium prepared with exosome-free serum for 3 days, and collect the culture medium and store it temporarily at 4°C. S2, Culture medium pretreatment Before ultracentrifugation, the culture medium was pretreated to remove cell debris and large extracellular vesicles. The culture medium was centrifuged at 1000 g for 15 min at 4 °C to remove dead cells; centrifuged at 2500 g for 20 min at 4 °C to remove cell debris; and centrifuged at 10000 g for 30 min at 4 °C to remove large extracellular vesicles. The pretreated culture medium was then temporarily stored at 4 °C.
[0097] S3, Ultracentrifugation The pretreated culture medium was centrifuged using an ultracentrifuge at 100,000g for 70 min, and the supernatant was discarded after centrifugation. S4, Exosome enrichment Exosomes precipitated at the bottom of the ultracentrifuge tube were resuspended in 1 ml binding buffer and the protein concentration was determined; 25 μg / ml protein was added to 0.3 mg A-PBA magnetic beads, and the mixture was shaken at 20 °C for 2 hours with a shaking speed of 30 rpm. S5. Elution of exosomes: Discard the supernatant, wash with elution buffer, add 100-200 μL of binding buffer, and elute by shaking at room temperature for 0.5-2 hours. After elution, perform solid-liquid separation using magnetic adsorption. Adjust the pH of the supernatant to 7.0 with 0.1 M NaOH to complete the enrichment.
[0098] It should be noted that this application is not limited to the above-described embodiments. The above embodiments are merely examples, and any embodiments with the same structure and effect as the technical concept within the scope of this application are included in the technical scope of this application. Furthermore, various modifications that can be conceived by those skilled in the art to the embodiments, and other ways of constructing by combining some of the constituent elements of the embodiments, without departing from the spirit of this application, are also included in the scope of this application.
Claims
1. A phenylboronic acid magnetic bead reagent kit for the enrichment of exosomes from multiple cancer types, characterized in that: The kit includes A-PBA magnetic beads, binding buffer, elution buffer, and neutralization buffer; the preparation process of the A-PBA magnetic beads is as follows: (1) Preparation of amino-modified iron oxide magnetic spheres: FeCl3·6H2O and anhydrous sodium acetate were dissolved in ethylene glycol, mixed and then 1,6-hexanediamine was added. After hydrothermal reaction and washing, NH2-Fe3O4 was obtained. (2) Preparation of agarose magnetic spheres: Agarose aqueous solution containing NH2-Fe3O4 was mixed with an oil solution, and Fe3O4@Aga microspheres were obtained by high-speed shear emulsification, alternating hot and cold solidification, and washing. (3) Epoxy crosslinking: Fe3O4@Aga microspheres were reacted with a bi-epoxy crosslinking agent under alkaline conditions to obtain epoxy crosslinked magnetic agarose microspheres A-BDGE; (4) Connecting to polyethyleneimine: A-BDGE microspheres are reacted with polyethyleneimine solution, and the epoxy groups are connected to the amino groups of PEI through ring opening to obtain PEI-grafted magnetic agarose microspheres A-PEI; (5) Connecting phenylboronic acid: A-PEI microspheres are reacted with phenylboronic acid derivatives containing aldehyde groups in the presence of a reducing agent. Through the reduction amination reaction of aldehyde groups with amino groups on PEI, phenylboronic acid groups are immobilized on the surface of microspheres to obtain the final product A-PBA magnetic spheres.
2. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The binding buffer is PBS with pH=2; the elution buffer is PBS with pH=7 containing 500 mM NaCl; and the neutralization solution is 0.1M NaOH.
3. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The mass-to-volume ratio of FeCl3·6H2O and anhydrous sodium acetate in step (1) is 1 mg: 0.1-0.4 mL.
4. The phenylboronic acid magnetic ball reagent kit according to claim 3, characterized in that: The mass-to-volume ratio of FeCl3·6H2O and anhydrous sodium acetate in step (1) is 1 mg: 2 mL.
5. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The volume-to-mass ratio of ethylene glycol and FeCl3·6H2O in step (1) is 12-20 mL: 1 g.
6. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The mass ratio of 1,6-hexanediamine and FeCl3·6H2O in step (1) is 5-8:
1.
7. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The oil phase solution mentioned in step (2) is a solution composed of liquid paraffin and Span 80, and the volume ratio of liquid paraffin to Span 80 is 25-30:
1.
8. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The aqueous solution mentioned in step (2) is a mixed suspension of agarose solution and NH2-Fe3O4, wherein the mass concentration of the agarose solution is 3-5% and the volume of the agarose solution is 0.8-1.2% of the mass of NH2-Fe3O4.
9. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The specific steps of step (2) are as follows: The oil phase solution was preheated at 75-85℃; the aqueous phase solution was stirred and mixed at 90-95℃ and 800-1200 rpm, and then added to the preheated oil phase. The mixture was emulsified at 18000-22000 rpm in a water bath at 75-85℃ for 10-20 min, and then transferred to an ice bath for another 8-15 min to obtain the product. The product was washed successively with petroleum ether, anhydrous ethanol and deionized water to obtain Fe3O4@Aga.
10. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The alkaline solution mentioned in step (3) is a sodium hydroxide solution containing NaBH4; the concentration of the sodium hydroxide solution is 0.5-1.0 mol / L; and the concentration of NaBH4 in the sodium hydroxide solution is 1-3 mg / mL.
11. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The specific steps of step (3) are as follows: Fe3O4@Aga microspheres were mixed with NaOH solution and stirred at 30-40℃ and 120-180 rpm for 20-40 min. Then BDGE and DMSO were added, wherein the volume-to-mass ratio of BDGE to Fe3O4@Aga microspheres was 150-200 μL:1 mg; the volume ratio of DMSO to BDGE was 0.5-0.8:1, and the reaction was continued for 4-8 h. After the reaction was completed, the mixture was washed with deionized water to obtain A-BDGE.
12. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The mass ratio of A-BDGE microspheres to polyethyleneimine in step (4) is 1:40-60.
13. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The phenylboronic acid derivative containing an aldehyde group mentioned in step (5) is 2,4-difluoro-3-formylphenylboronic acid.
14. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The specific steps of step (5) are as follows: A-PEI microspheres are added to an anhydrous ethanol solution containing sodium cyanoborohydride, ultrasonically dispersed, and then 2,4-difluoro-3-formylphenylboronic acid is added. The mixture is shaken at room temperature for 10-14 h. After the reaction is completed, the mixture is washed alternately with ethanol and pure water to obtain A-PBA.
15. The phenylboronic acid magnetic ball reagent kit according to claim 1, characterized in that: The mass ratio of 2,4-difluoro-3-carboxyphenylboronic acid to A-PEI microspheres is 0.8-1.2:
1.
16. The phenylboronic acid magnetic ball reagent kit according to any one of claims 1-15, characterized in that: The preparation method of the A-PBA magnetic spheres includes the following steps: (1) Preparation of amino-modified iron oxide magnetic spheres: FeCl3•6H2O and anhydrous sodium acetate powder were weighed in a 1:2 mass ratio, and ethylene glycol was added to each. The mixture was then sonicated to dissolve the powder, yielding anhydrous sodium acetate ethylene glycol solution and FeCl3•6H2O ethylene glycol solution. The anhydrous sodium acetate ethylene glycol solution was poured into the FeCl3•6H2O ethylene glycol solution and stirred until homogeneous to obtain a mixed solution. Then, 1,6-hexanediamine (6.5 times the mass of FeCl3•6H2O) was added to the mixed solution, and the mixture was sonicated until homogeneous. The mixture was then poured into a high-temperature and high-pressure reactor and reacted at 198°C for 6 h. After the reaction was completed, the product was washed several times with anhydrous ethanol and pure water to obtain amino-modified iron oxide magnetic spheres, abbreviated as NH2-Fe3O4. (2) Preparation of agarose magnetic beads: The oil phase consisted of a mixture of liquid paraffin and Span 80 at a volume ratio of 26:1, preheated in an 80°C water bath. The aqueous phase consisted of a 4% agarose solution at a volume ratio of 1:10 and a mixed suspension of NH2-Fe3O4 magnetic balls, mechanically stirred at 1000 rpm in a 95°C water bath until homogeneous. The mixed sugar suspension was rapidly transferred to the oil phase. The mixture was emulsified in an 80°C water bath at 20,000 rpm for 15 min using a high-speed shear mill, followed by emulsification in an ice bath for another 10 min. The product was washed several times with petroleum ether, anhydrous ethanol, and deionized water to obtain Fe3O4@Aga. (3) Cross-linked epoxy groups: Fe3O4@Aga microspheres (5:1 by mass / volume ratio) were mixed with a 0.6 mol / L NaOH solution containing 2 mg / mL NaBH4. The mixture was stirred at 150 rpm for 30 min in a 35°C water bath. Then, BDGE and DMSO (1.6:1 by volume ratio) were added, and the reaction was continued for 6 h to obtain Fe3O4@Aga-BDGE microspheres. The Fe3O4@Aga-BDGE microspheres were washed several times with deionized water to obtain A-BDGE. (4) Connecting polyethyleneimine: A homogeneous solution was obtained by mixing PEI 1800he and 50 mmol / L sodium bicarbonate aqueous solution at a mass-to-volume ratio of 1:3.
2. This solution was then added to a beaker containing 50 mg of A-BDGE microspheres, and the mixture was ultrasonically dispersed and reacted at 70°C and 400 rpm for 12 h. After the reaction was completed, the microspheres were washed with ultrapure water and magnetically separated to obtain PEI-grafted magnetic agarose microspheres, which are A-PEI. (5) Connecting phenylboronic acid: Weigh A-PEI microspheres (2.5:1 by mass ratio) and anhydrous ethanol containing 1% sodium cyanoborohydride, and ultrasonically disperse them into a homogeneous solution. Then, add 50 mg of 2,4-difluoro-3-carboxyphenylboronic acid (2,4-DFPBA) to the homogeneous solution and shake in a shaker at room temperature for 12 h. After the reaction, wash the solution with ethanol and pure water alternately several times to obtain phenylboronic acid-functionalized magnetic agarose microspheres.
17. The application of the phenylboronic acid magnetic ball kit according to any one of claims 1-16 in the enrichment and isolation of exosomes from plasma, serum, urine, breast milk, cerebrospinal fluid, tumor ascites, saliva, and cell culture supernatant.
18. The application according to claim 17, characterized in that: The tumor in question is lung cancer, breast cancer, colon cancer, or pancreatic cancer.
19. A method for enriching and separating exosomes using the phenylboronic acid magnetic bead kit according to any one of claims 1-16, characterized in that: Includes the following steps: S1. Collect the culture medium. Select A549 cells in good growth condition and culture them until the culture dish is 70% full; discard the culture medium, wash twice with PBS, culture A549 cells in RIPM 1640 complete culture medium prepared with exosome-free serum for 3 days, collect the culture medium and store it temporarily at 4°C. S2, Culture medium pretreatment Pre-treatment before ultracentrifugation was performed to remove cell debris and large extracellular vesicles from the conditioned medium. The culture medium was centrifuged at 4°C and 1000 g for 15 min to remove dead cells. Remove cell debris by centrifugation at 2500 g for 20 min at 4°C; Large extracellular vesicles were removed by centrifugation at 10,000 g for 30 min at 4 °C, and the pretreated culture medium was temporarily stored at 4 °C. S3, Ultracentrifugation The pretreated culture medium was centrifuged using an ultracentrifuge at 100,000g for 70 min, and the supernatant was discarded after centrifugation. S4, Exosome enrichment Exosomes precipitated at the bottom of the ultracentrifuge tube were resuspended in 1 ml of binding buffer and the protein concentration was determined. 0.3-0.5 mg of A-PBA magnetic beads were added at a protein concentration of 25 μg / ml, and the mixture was shaken at room temperature for 2 hours at a shaker speed of 30 rpm. S5. Elution of exosomes: Discard the supernatant, wash with elution buffer, add 100-200 μL of binding buffer, and elute by shaking at room temperature for 0.5-2 hours. After elution, perform solid-liquid separation using magnetic adsorption. Adjust the pH of the supernatant to 7.0 with 0.1 M NaOH to complete the enrichment.
Citation Information
Patent Citations
Large-scale exosome enrichment technology for reducing exosome damage
CN114940699A
Exosome enrichment by ultrafiltration
CN115678832A
Nano magnetic material of surface modified boric acid base group, preparation method and application thereof
CN101684005A
